Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingkun Xu

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
International Journal of Medical Sciences|November 11, 2020
Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinomaGuangzhen Wu, Yingkun Xu, Lin Li, et al.
Oncotargets and Therapy|March 17, 2021
RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt PathwayChenglin Han, Shuxiao Chen, Haiyang Ma, et al.
Journal of Cancer Research and Therapeutics|July 16, 2021
The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guérin vaccine therapy in patients with nonmuscle invasive bladder cancerZilong Wang, Chenglin Han, Yingkun Xu, et al.
Journal of Immunology Research|June 13, 2022
Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast CancerYingkun Xu, Dan Shu, Meiying Shen, et al.
Journal of Oncology|May 2, 2022
Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer PatientsYingkun Xu, Yang Peng, Meiying Shen, et al.
Analytical Cellular Pathology (Amsterdam)|March 10, 2021
Comparison of the Fatty Acid Metabolism Pathway in Pan-Renal Cell Carcinoma: Evidence from BioinformaticsPing Wu, Yingkun Xu, Jiayi Li, et al.
Biomed Research International|September 9, 2022
Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-CancerYingkun Xu, Meiying Shen, Yang Peng, et al.
Pathology, Research and Practice|July 19, 2023
Sphingosine kinase 1 regulates lipid metabolism to promote progression of kidney renal clear cell carcinomaLeizuo Zhao, Zicheng Wang, Yingkun Xu, et al.
Journal of Oncology|September 5, 2022
Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast CancerYingkun Xu, Yudi Jin, Shun Gao, et al.
Journal of Oncology|September 19, 2022
Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer PatientsYingkun Xu, Han Li, Ailin Lan, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
International Journal of Medical Sciences|November 11, 2020
Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinomaGuangzhen Wu, Yingkun Xu, Lin Li, et al.
Oncotargets and Therapy|March 17, 2021
RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt PathwayChenglin Han, Shuxiao Chen, Haiyang Ma, et al.
Journal of Cancer Research and Therapeutics|July 16, 2021
The role of prostate-specific antigen and multiparametric magnetic resonance imaging in the diagnosis of granulomatous prostatitis induced by intravesical Bacillus Calmette-Guérin vaccine therapy in patients with nonmuscle invasive bladder cancerZilong Wang, Chenglin Han, Yingkun Xu, et al.
Journal of Immunology Research|June 13, 2022
Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast CancerYingkun Xu, Dan Shu, Meiying Shen, et al.
Journal of Oncology|May 2, 2022
Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer PatientsYingkun Xu, Yang Peng, Meiying Shen, et al.
Analytical Cellular Pathology (Amsterdam)|March 10, 2021
Comparison of the Fatty Acid Metabolism Pathway in Pan-Renal Cell Carcinoma: Evidence from BioinformaticsPing Wu, Yingkun Xu, Jiayi Li, et al.
Biomed Research International|September 9, 2022
Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-CancerYingkun Xu, Meiying Shen, Yang Peng, et al.
Pathology, Research and Practice|July 19, 2023
Sphingosine kinase 1 regulates lipid metabolism to promote progression of kidney renal clear cell carcinomaLeizuo Zhao, Zicheng Wang, Yingkun Xu, et al.
Journal of Oncology|September 5, 2022
Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast CancerYingkun Xu, Yudi Jin, Shun Gao, et al.
Journal of Oncology|September 19, 2022
Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer PatientsYingkun Xu, Han Li, Ailin Lan, et al.
Pageof 7